Peptide therapy is popular for its relatively low side effects
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial - Springer Nature Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide - The Journal of Clinical Endocrinology & Metabolism Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist - JCI Insight Fibre intake for optimal health: how can healthcare professionals support people to reach dietary recommendations
Unlike Mounjaro and Zepbound, which come in injection pens, our compounded tirzepatide is provided in vials with syringes
At Klinic, we pride ourselves on removing the barriers that stand between you and better health
There have been rare reports of pancreatitis (inflammation of the pancreas) in patients taking GLP-1 receptor agonists, though a definitive causal relationship remains uncertain
Professor Jastreboffs research contributions include: Principal investigator for GLP3 phase 2 obesity trial demonstrating 24.2% weight loss Leadership in clinical research examining triple hormone receptor agonists Extensive investigations of incretin-based therapies for obesity and metabolic disease Pioneering work on combination approaches to weight management Studies examining neurobiological mechanisms underlying obesity pharmacotherapy Her work has helped establish GLP3 as one of the most promising next-generation obesity treatments in clinical development, contributing to the scientific foundation for multi-pathway metabolic interventions
